In this sixth installment, Paula and Susanne discuss how they explain the importance of biomarker testing to patients with endometrial cancer and how the use of biomarker testing has advanced the field of oncology. Read More ›

In this fifth installment, Paula and Susanne discuss the clinical factors they consider when evaluating treatment options for patients with endometrial cancer. Read More ›

In this fourth installment, Paula and Susanne discuss the types of additional support resources, both emotionally and practically, they recommend for patients diagnosed with endometrial cancer. Read More ›

In this third installment, Paula and Susanne discuss how they initiate a conversation with their patients about treatment options and the educational materials they use to support patients in understanding their treatment journey with endometrial cancer. Read More ›

In this second installment, Paula and Susanne discuss how personalized medicine is changing the landscape of endometrial cancer treatment and how it is impacting patient care, as well as how they stay current with new guidelines and data. Read More ›

In this first installment, Paula and Susanne discuss the most common side effects patients experience during treatment for advanced endometrial cancer, how they can be managed, and how to effectively educate patients on managing side effects at home. Read More ›

In this ninth installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations for using NALIRIFOX or FOLFIRINOX when treating patients with pancreatic cancer. Read More ›

In this eighth installment, Shubham Pant, MD, and Michael Pishvaian, MD, PhD, discuss their approach on deciding which treatment options, FOLFIRINOX or NALIRIFOX, are best suited for the patients that they treat. Read More ›

In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.

Read More ›

In this sixth installment, Tanios Bekaii-Saab, MD, and Shubham Pant, MD, discuss the role cost plays in selecting cancer regimens.

Read More ›